Navigation Links
Radioimmunotherapy deemed safe and effective for lymphoma patients
Date:7/10/2013

Reston, Va. (July 10, 2013) A new treatment option for patients with relapsing follicular, mantle cell and other indolent B-cell lymphomas has been determined safe and feasible by researchers exploring the potential of a low energy beta-emitter radiopharmaceutical. According to data published in the July issue of The Journal of Nuclear Medicine, the use of 177Lu-DOTA-rituximab as a radioimmunotherapy results in a high rate of tumor response while using less radiation than current therapies.

"Twelve years ago, when we started the study, it seemed that radioimmunotherapy could be a highly interesting tool that was both easy for clinicians to use and well-tolerated in patients. It also was clear that the use of iodine radionuclides was inconvenient for handling and not practical for patients because of the need for prolonged in hospital days due to radiation protection measures," said Andreas Lohri, MD, lead author of the study "Radioimmunotherapy with 177Lu-DOTA-Rituximab: Final Results of a Phase I/II Study in 31 Patients with Relapsing Follicular, Mantle Cell, and Other Indolent B-Cell Lymphomas." "Although 90Y ibritumomab tiuxetanZevalinwas introduced shortly after we started the study, we felt it was important to do clinical experiments with other radionuclides."

The prospective study included 31 patients with histologically confirmed relapsed or refractory CD20-positive B-cell lymphoma. All patients received an initial dose of 740 MBq/m2 body surface area of 177Lu-DOTA rituximab.. Doses were increased in steps of 185 MBq/m2 over a maximum of seven doses. Hematologic and nonhematologic toxicity was measured weekly up to week 10 or until recovery from the lowest level of blood cell count. Imaging with whole body computed tomography (CT) and 18F-FDG positron emission tomography (PET) or 18F-FDG PET/CT was conducted at baseline and at 8-12 weeks.

The maximum tolerated dose using 177Lu-DOTA rituximab was 1,665 MBq/m2. Toxicity was mainly hematologic, with thrombocytopenia and leukopenia noted as the dose-limiting toxicities, and nonhematologic toxicity was minor. Clinical responses occurred at all dose levels for patients with follicular (82 percent overall response rate) and mantle cell (21 percent response rate) lymphomas. With a median follow-up of almost seven years, the estimated median time of survival after radioimmunotherapy was four years.

"With 177Lu-DOTA Rituximab we can essentially do CD20 imaging," said Lohri. "At the moment, this may be academically interesting and could potentially be used in daily practice if compared to all forms of current PET imaging."


'/>"/>

Contact: Susan Martonik
smartonik@snmmi.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. Radioimmunotherapy could extend lives of advanced lymphoma patients
2. Talk Therapy Can Ease Depression, But No Single Type Deemed Best
3. Airports in N.Y., L.A., Hawaii Deemed Worst for Pandemic Spread
4. Study shows SBRT for stage I NSCLC safe and effective
5. New research finds flu shot effective regardless of circulating flu strain
6. Virus combination effective against deadly brain tumor, Moffitt Cancer Center study shows
7. Long-term study reports deep brain stimulation effective for most common hereditary dystonia
8. Effective Environmental Services Launch New Websites to Serve Customers
9. Provant CEO, Heather Provino, Shares Key Insights on Employee Engagement & Effective Incentive Program Design at SHRM
10. Alta White Teeth Whitening System Now Available in New Package for Effective Results at Home
11. Animal thyroid extract as effective as T4 in treating hypothyroidism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... ... for its innovative EcoQube Frame vertical micro-veggies garden on Kickstarter . Surpassing ... the product – with nearly 2,000 consumers (and counting) already backing the campaign. ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... that they are now offering treatments for sleep apnea and TMJ at their ... Sleep apnea , specifically the obstructive type, is increasingly being treated at ...
(Date:3/24/2017)... ... March 24, 2017 , ... The law firm of ... is pleased to announce Westchester resident Lauren C. Enea has joined the firm as ... firm, will concentrate her practice in elder law, Medicaid planning and applications, and Wills, ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro Health ... partnership to prep patients for colonoscopy at the HyGIeaCare® Center that is to ... Miami, FL. , The HyGIeaCare® Prep, cleared by the U.S. Food ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... first Certified Medical Reiki™ Master in Frederick, MD. Judy says, “I am passionate ... during what is often a very difficult and challenging time.” , A Certified ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... 24, 2017  Zymo Research Corp., also ... Robotics, Inc., who designs, manufactures and distributes ... that teams Zymo Research,s DNA methylation detection ... extraction products with Hamilton,s high-throughput automation platforms. ... for microbiomics and RNA isolation for use ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Dental Implants ... ... for Dental Implants in US$ Million. The report provides separate comprehensive analytics ... , Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2015 through 2022. ...
(Date:3/24/2017)... -- FinancialBuzz.com News Commentary  ... According to new data published ... the legal cannabis market is projected to continue to grow ... from the current presidential administration. The report created by Arcview,s ... of growth in this industry are the passage and subsequent ...
Breaking Medicine Technology: